AQR Capital Management LLC Boosts Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

AQR Capital Management LLC boosted its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 1,018.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 256,342 shares of the company’s stock after acquiring an additional 233,422 shares during the quarter. AQR Capital Management LLC owned 0.22% of Humacyte worth $1,230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after buying an additional 896,415 shares during the period. Renaissance Technologies LLC boosted its position in shares of Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Marshall Wace LLP increased its position in Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after buying an additional 450,031 shares in the last quarter. Private Advisor Group LLC raised its stake in Humacyte by 15.4% during the second quarter. Private Advisor Group LLC now owns 366,600 shares of the company’s stock valued at $1,760,000 after buying an additional 48,976 shares during the last quarter. Finally, Capstone Investment Advisors LLC purchased a new stake in shares of Humacyte in the first quarter worth $972,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Benchmark reiterated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday. BTIG Research upped their price objective on Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $9.80.

Insider Activity

In related news, CEO Laura E. Niklason sold 277,090 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the transaction, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Laura E. Niklason sold 277,090 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the transaction, the chief executive officer now directly owns 4,029,374 shares in the company, valued at approximately $26,070,049.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares in the company, valued at $28,896,373.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. 11.20% of the stock is currently owned by company insiders.

Humacyte Stock Performance

HUMA opened at $5.73 on Friday. The stock has a market cap of $683.88 million, a P/E ratio of -4.55 and a beta of 1.45. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The firm has a fifty day moving average price of $6.08 and a 200 day moving average price of $5.79. Humacyte, Inc. has a 1 year low of $1.96 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA) last released its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Equities research analysts anticipate that Humacyte, Inc. will post -1.09 earnings per share for the current year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.